On June 1, 2026, Evercore ISI Group reaffirmed its positive outlook on C4 Therapeutics (NASDAQ: CCCC). The investment bank maintained an "Outperform" rating on the company's stock.
Evercore ISI also raised its price target for C4 Therapeutics. The target increased by over 71%, moving from $7.00 to $12.00.
This upward revision reflects growing confidence in C4 Therapeutics. The clinical-stage biopharmaceutical company develops a new class of medicines through targeted protein degradation.
The updated analyst rating suggests strong belief in the company's strategy and its oncology pipeline.